Valuation: Novacyt

Market Cap 27.97M 31.95M 25.82M 24.08M 45.38M 3.02B 46.19M 310M 120M 1.49B 120M 117M 5.19B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 29.93M 34.19M 27.63M 25.77M 48.55M 3.23B 49.42M 331M 129M 1.6B 128M 126M 5.56B EV / Sales 2026 *
0.98x
EV / Sales 2027 * 0.94x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+0.88%
1 week+4.55%
Current month-30.86%
1 month-28.12%
3 months+0.29%
6 months-1.15%
Current year-2.68%
1 week 33
Extreme 33
46.2
1 month 33
Extreme 33
51.8
Current year 26.6
Extreme 26.6
86
1 year 26.6
Extreme 26.6
86
3 years 26.6
Extreme 26.6
137
5 years 26.6
Extreme 26.6
497.3
10 years 6.03
Extreme 6.03
1,270
Manager TitleAgeSince
Chief Executive Officer 53 30/04/2024
Director of Finance/CFO 44 31/12/2019
Chief Operating Officer - 31/10/2021
Director TitleAgeSince
Director/Board Member 75 02/07/2006
Director/Board Member 60 26/06/2017
Director/Board Member 44 01/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
+0.88%+4.55% - - 31.94M
-3.20%+1.47%-38.05%-42.74% 582M
-8.07%+12.50%+188.46% - 502M
-3.84%-3.84%-33.12%+15.70% 130M
-1.24%-0.62%+57.14%+108.50% 126M
Average -3.09%-1.46%+43.61%+27.15% 335.33M
Weighted average by Cap. -4.77%+0.10%+56.20%-10.90%

Financials

2026 *2027 *
Net sales 30.52M 34.87M 28.18M 26.28M 49.52M 3.3B 50.41M 338M 131M 1.63B 131M 128M 5.67B 34.86M 39.83M 32.18M 30.02M 56.56M 3.77B 57.57M 386M 150M 1.86B 150M 146M 6.47B
Net income - -
Net Debt 1.96M 2.23M 1.81M 1.68M 3.17M 211M 3.23M 21.66M 8.41M 104M 8.4M 8.21M 363M 4.84M 5.53M 4.47M 4.17M 7.86M 523M 8M 53.61M 20.81M 258M 20.78M 20.32M 899M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
30/06/26 GBX 34.50 +0.88% 75,441
29/06/26 GBX 34.20 +1.48% 56,291
26/06/26 GBX 33.70 -0.88% 82,430
25/06/26 GBX 34.00 -5.29% 194,718
24/06/26 GBX 35.90 +8.79% 1,317,977

Annual profits - Rate of surprise